Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …

Antidiabetic sodium-glucose cotransporter 2 (SGLT2) inhibitors have attracted attention for
their cardiorenal-protective properties beyond their glucose-lowering effect. However, their …

Hyperglycemia is one of the ischemic neuronal damage triggers that exacerbate the
response to oxidative stress, inflammation, and apoptosis induced by cerebral …

Sodium–glucose cotransporter type 2 inhibitors (SGLT2i) have proven cardioprotective
properties, which makes this class of drugs one of the priorities in the treatment of patients …

Ischemic stroke is a serious condition associated with severe functional disability and high
mortality, however; effective therapy remains elusive. Empagliflozin, a sodium-glucose …

PowerPoint 演示文稿 Page 1 EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2
DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION Publication Date: 2020-03-28 …

Brain swelling is a major cause of death and disability in ischemic stroke. Drugs of the
gliflozin class, which target the Na+-coupled D-glucose cotransporter, SGLT2, are approved …

Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people
without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke …

Diabetes mellitus is a major risk factor for cardiovascular morbidity and mortality. Current
therapeutic strategies have not provided constant beneficial cardiovascular-related results …

Objectives This study aimed to evaluate the effects of the antidiabetics liraglutide, a GLP‐1
analog, and empagliflozin, an SGLT‐2 inhibitor, on the brain microcirculation of diabetic rats …